https://www.selleckchem.com/pr....oducts/tc-s-7009.htm
The combination of Birinapant with Ralimetinib, inhibitor of p38α, restores the sensitivity of LKB1- and KRAS-mutated cell lines to the IAP inhibitor Birinapant. Our study shows how the use of Birinapant could be a viable therapeutic option for patients with LKB1-mutated NSCLCs. In addition, combination of Birinapant and a KRAS pathway inhibitor, as Ralimetinib, could be useful for patients with LKB1 and KRAS-mutated NSCLC. This study aimed to explore the potential of magnetic resonance imaging (MRI) radiomics-based machine learning t
Like
Comment
Share
